Low-dose valganciclovir for cytomegalovirus prophylaxis in heart transplant recipients

Transplantation Proceedings

Volumn 45, Issue 9, 2013, Pages 3414-3417

  Julian, K G ^a   Shattahi, E ^a   Burg, J E ^a   Boehmer, J P ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS; VALGANCICLOVIR;

ARTICLE; CARDIAC GRAFT REJECTION; CYTOMEGALOVIRUS INFECTION; GRAFT RECIPIENT; HEART TRANSPLANTATION; INFECTION PREVENTION; LEUKOPENIA; LOW DRUG DOSE; NEUTROPENIA; NEUTROPHIL COUNT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; COHORT STUDIES; CYTOMEGALOVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; GANCICLOVIR; HEART TRANSPLANTATION; HUMANS;

EID: 84887056297     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2013.08.023     Document Type: Article

References (14)

1. T.C. Merigan, D.G. Renlund, and S. Keay A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation N Engl J Med 326 1992 1182 1186
2. E.M. Hodson, M. Ladhani, A.C. Webster, G.F. Strippoli, and J.C. Craig Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients Cochrane Database Syst Rev 2 2013 CD003774
3. M.D. Pescovitz, J. Rabkin, and R.M. Merion Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients Antimicrob Agents Chemother 44 2000 2811 2815
4. C. Paya, A. Humar, and E. Dominguez Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients Am J Transplant 4 2004 611 620
5. C.E. Chamberlain, S.R. Penzak, and R.M. Alfaro Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients Am J Transplant 8 2008 1297 1302
6. A.C. Kalil, C. Mindru, and D.F. Florescu Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis Clin Infect Dis 52 2011 313 321
7. J.K. Walker, L.M. Scholz, and M.H. Scheetz Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction Transplantation 83 2007 874 882
8. S. Gabardi, C.C. Magee, S.A. Baroletti, J.A. Powelson, J.L. Cina, and A.K. Chandraker Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis Pharmacotherapy 24 2004 1323 1330
9. A. Humar, Y. Lebranchu, and F. Vincenti The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients Am J Transplant 10 2010 1228 1237
10. F.L. Luan, M. Kommareddi, and A.O. Ojo Impact of cytomegalovirus disease in D+/R- kidney transplant patients receiving 6 months low-dose valganciclovir prophylaxis Am J Transplant 11 2011 1936 1942
11. C.N. Kotton, D. Kumar, and A.M. Caliendo International consensus guidelines on the management of cytomegalovirus in solid organ transplantation Transplantation 89 2010 779 795
12. Valganciclovir. Lexicomp Online. Available at: http://www.crlonline.com. Accessed November 10, 2012.
13. J.M. Park, K.D. Lake, J.D. Arenas, and R.J. Fontana Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients Liver Transpl 12 2006 112 116
14. R.L. Brady, K. Green, C. Frei, and P. Maxwell Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients Transpl Infect Dis 11 2009 106 111